BioSig Technologies Inc (OTCMKTS:BSGM) is a micro-cap name in the medical device space that has started to catch some upward momentum. While we suspect that there is some investor awareness activity going on here, it’s also an interesting story in its own right due to the company’s proprietary technology platform through its PURE EP System. PURE EP is a surface electrocardiogram and intracardiac multichannel recording and analysis system designed to assist electrophysiologists.
“I am extremely pleased with the recent achievements that we have made, and believe that now is an ideal time to provide an in-depth overview of the Company to the investment community,” stated Mr. Gregory Cash, President and CEO of BioSig Technologies in the company’s recent letter to shareholders. “Since inception, our management has been focused on building a strong platform of best-in-class technologies coupled with strategic industry relationships. I feel that we are now well positioned to leverage those assets within the rapidly growing medtech marketplace. I have no doubt, that the introduction of BioSig’s PURE EP System will be a significant advancement in addressing the multi-billion dollar Electrophysiology market. Going forward, we are committed to commercializing this product on a global scale, uplisting to a more senior exchange and enhancing overall shareholder value.”
BioSig Technologies Inc (OTCMKTS:BSGM) bills itself as a medical device company that is developing a proprietary technology platform aimed at the rapidly growing $4 billion electrophysiology (EP) marketplace.
Led by a proven management team, world-class Board of Directors and Scientific Advisory Board, Minneapolis-based BioSig Technologies is preparing to commercialize its PURE EP System. PURE EP is a surface electrocardiogram (ECG) and intracardiac multichannel recording and analysis system designed to assist electrophysiologists in making crucial clinical decisions in real-time.
PURE EP acquires and displays high-fidelity cardiac signal recordings even at undetectable levels (until now) with high-accuracy to help identify appropriate catheter ablation targets – areas of tissue to destroy that otherwise create a heart rhythm disturbance (arrhythmia). PURE EP is an innovative platform, offering benefits over current technologies including increased accuracy, reduced noise and interference, clinical information previously not available and potential elimination of repeat procedures.
BioSig is collaborating with prestigious cardiac arrhythmia centers including Mayo Clinic, Mt Sinai, Texas Cardiac Arrhythmia Institute, UH Case Medical Center, and Bringham and Women’s Hospital to develop, refine and, ultimately, commercialize its novel information system.
Find out when $BSGM stock reaches critical levels. Subscribe to OracleDispatch.com Right Now by entering your Email in the box below.
The company just had its technology featured in the Journal of the American College of Cardiology (JACC): Clinical Electrophysiology. That may end up being important exposure, and the stock has taken flight in part due to this publication.
The article entitled Novel Electrophysiology Signal Recording System Enables Specific Visualization of the Purkinje Network and Other High-Frequency Signals highlights the potential benefits of using BioSig’s PURE EP System compared to a standard recording system. The study was completed by the team led by Dr. Samuel Asirvatham at Mayo Clinic in Rochester, Minnesota.
“We are pleased to have such a prestigious journal recognize the potential advantages of the PURE EP System,” said Jay Millerhagen, BioSig’s Vice President of Clinical Research. The study focused on signals from the Purkinje network in the heart’s ventricles or lower chambers of the heart. Many ventricular arrhythmias are initiated in the Purkinje fiber conduction system.
Ventricular arrhythmias are a major source of sudden death, which accounts for approximately half of cardiac mortality. This study proved that by using BioSig’s PURE EP System during catheter ablation, doctors may be better able to treat these types of complex arrhythmias.
We’ve witnessed 25% piled on for shareholders of the company during the trailing week. The situation may be worth watching. BSGM is a stock who’s past is littered with sudden rips. Moreover, the listing has benefitted from a jump in recent trading volume to the tune of approaching 310% above the average volume levels in play in this stock over the longer term.
Traders should note this as important with a float in play that’s tight — barely over 11M shares. One is wise to respect the dynamic this may create — with such a tight trading float, this kind of ramping interest can force a supply-shock squeeze.
Currently trading at a market capitalization of $36M, BSGM has a bankroll ($150K) of cash on the books, which is balanced by 3.38M in total current liabilities. The company is pre-revenue at this point. This is an exciting story, and we look forward to a follow-up chapter as events transpire. For continuing coverage on shares of $BSGM stock, as well as our other hot stock picks, sign up for our free newsletter today and get our next hot stock pick!